Hematology

Register for your FREE account now and join the thousands of healthcare professionals who have depended on us for over 26 years for accurate, concise, and timely drug information.

Email*

Password*

Keep me logged in Forgot your password?

Email*

Hematology Resource Center

Welcome to the MPR Hematology Resource Center, where you will find everything you need to make informed clinical decisions.

Drug Monographs

Click on the subcategory below to find drug monographs for that particular area.

News

Causality Link Between HDL Cholesterol, MI Challenged

Genetic mechanisms that are associated with high plasma levels of high-density lipoprotein (HDL) cholesterol do not reduce the risk of myocardial infarction (MI), adding question to causality of link.

Statins Benefit Those at Low Risk for Vascular Events

Reduction of low-density lipoprotein (LDL) cholesterol with statins is associated with a decrease in major vascular events, even for individuals with a five-year risk of <10%.

Coffee Drinking Linked to Lower Mortality Risk

Coffee drinking is associated with a lower risk of death from most major causes except cancer.

Repeated Revascularization Doesn't Aid High-Risk Patients

For asymptomatic patients who are identified as high-risk by exercise echocardiography (ExE) after coronary revascularization, repeated revascularization is not associated with improved outcomes.

Trail Making Test Performance Predicts Post-Stroke Mortality

Poor executive performance, as measured with the Trail Making Test (TMT)-A and -B, can identify elderly men who are at higher risk of death after a first-ever stroke.

FERRIPROX

1/30/2012

ApoPharma USA Inc.

Pharmacological Class: Iron chelating agent.

Active Ingredient(s): Deferiprone 500mg; scored tabs.

Indication: Treatment of transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.

FIRAZYR

11/18/2011

Shire US, Inc.

Pharmacological Class: Bradykinin B2 receptor antagonist.

Active Ingredient(s): Icatibant 10mg/mL; soln for SC inj; preservative-free.

Indication: Treatment of acute attacks of hereditary angioedema (HAE).

BRILINTA

8/25/2011

AstraZeneca Pharmaceuticals

Pharmacological Class: P2Y₁₂ platelet inhibitor (cyclopentyltriazolopyrimidine).

Active Ingredient(s): Ticagrelor 90mg; tablets.

Indication: To reduce the rate of thrombotic cardiovascular (CV) events in patients with acute coronary syndrome (ACS) (unstable angina or non-ST-elevation myocardial infarction [MI] or ST-elevation MI).